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TDF/FTC+ATV/r, £85,477 for ABC/3TC+EFV, and £99,609 for ABC/3TC+ATV/r. At a will-
ingness-to-pay threshold of £30,000 per QALY gained, TDF/FTC-based regimens were 
predicted to be cost-effective compared with ABC/3TC-based regimens, with incre-
mental cost-effectiveness ratios of £20,545 for TDF/FTC+EFV versus ABC/3TC+EFV 
and £20,652 for TDF/FTC+ATV/r versus ABC/3TC+ATV/r. In subgroup analyses, TDF/
FTC-based regimens were predicted to yield more QALYs and to remain cost-effec-
tive compared with ABC/3TC-based regimens. ConClusions: In an analysis of 
the regimens examined in the ACTG 5202 clinical trial for treatment-naïve adults 
with HIV-1 infection, regimens containing TDF/FTC yielded more favorable health 
outcomes and were predicted to be cost-effective compared with regimens con-
taining ABC/3TC.
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objeCtives: The current recommendations for hepatitis C infection genotype 1 
include one protease inhibitor (IP), boceprevir or telaprevir, in addition to the pre-
vious standard dual therapy (DT) (peginterferon plus ribavirin). However, the cost 
of these new drugs imposes high financial burden in the health care systems. The 
aim of this study is to undertake a systematic review of the cost-effectiveness of 
boceprevir compared to telaprevir and DT. Methods: A systematic search was 
conducted in MEDLINE, EMBASE, Econlit and NHS-EED. Only full-text published 
manuscripts were considered and no further restriction were included. Relevant 
studies were selected by two independent researchers. Disagreements were resolved 
by discussion. A checklist was applied based on the CHEERS guideline to assess 
the quality of the studies. Results: Nine studies were found. Three compared 
Boceprevir versus DT whereas 6 compared both IP with DT. Six analyses were pre-
sented for naïve (no previously treated) patients and 5 analyses for patients previ-
ously treated. Comparators vary in terms of the schemes used and stopping rules 
applied. All studies modeled the disease properly. However, important differences 
in assumptions and parameters were found. Most studies adopted a national health 
system perspective. Only two studies used information from mixed treatment com-
parisons to be incorporated into the model. 8 out of 9 studies concluded that the IP 
is cost-effective for their corresponding jurisdiction. In naïve patients, two studies 
reported Telaprevir being cost-effective against Boceprevir and no study favored 
Boceprevir. In patients previously treated one study favors Boceprevir and two stud-
ies favors Telaprevir. ConClusions: The treatment with IP compared with DT is 
cost-effective in most jurisdictions where it has been evaluated. However, important 
variations were found in terms of patient´s subgroups and schemes of treatment. 
It cannot be concluded that one drug is more cost-effective than the other due to 
important structural uncertainty.
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objeCtives: Conduct a pharmacoeconomic analysis, cost-minimization type of 
therapy with linezolid in patients hospitalized between August, 2009 and December, 
2010 in a public hospital in Brazil. Methods: We conducted a retrospective cohort 
study at a Brazilian public hospital from August 1, 2009 through December 31, 2010. 
A cost-minimization analysis was undertaken for which patients used linezolid 
during the internment in this period, from the perspective of the Brazilian public 
health system. Results: The medical records of 61 patients were evaluated. Of all 
patients, 67.2% were male and mean age was 43.2 ± 17.8 years. The therapy with lin-
ezolid lasted 10.6 ± 4.7 days. The antibiogram was present in 65.6% of the records. In 
50.8% of cases, the bacteria were sensitive to linezolid. The main reason for the use 
of antibiotics was sepsis and nosocomial pneumonia (34.4% each). Sixteen (26.2%) 
patients met the criteria for changing the route of administration of the antimi-
crobial. Altogether, the cost of treatment with linezolid for these 16 patients was 
US$ 39.755,05. If it were adopted sequential therapy, the treatment would cost US$ 
31.744,28, which represents a saving of US$ 8.010,77 to the hospital. ConClusions: 
The results demonstrated the importance of pharmacoeconomic analysis of lin-
ezolid to the hospital, because in 17 months of cost analysis, these could have 
been reduced by 20,2% only with the switch antibiotic therapy. It is expected that 
results of studies such as this may contribute to the rational use of antimicrobials 
and resources for hospitals.
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objeCtives: Ontario, Canada, immunizes against influenza using a trivalent 
inactivated influenza vaccine (IIV3) under a Universal Influenza Immunization 
Program (UIIP). The UIIP offers IIV3 free of charge to all Ontarians over 6 months 
of age. A newly approved quadrivalent inactivated influenza vaccine (IIV4) offers 
wider protection against influenza B disease. In this study, we explore the expected 
cost-utility and budget impact of replacing IIV3 with IIV4 within the context of 
Ontario’s UIIP. Methods: We developed a model based on Ontario outcomes data 
published by Kwong and colleagues. We used Ontario based health care costs and 
Canadian based labor costs. Efficacy of IIV3 and IIV4 were estimated in a similar 
manner to a previous publication by Reed and colleagues. However, we improved 
by including emerging data from new meta-analyses on the efficacy of IIV3. These 
include new estimates of cross protection against mismatched B influenza offered 
by IIV3, as well as, new estimates of the vaccine efficacy in seniors. Conservatively, 
herd protection was not considered. Results: Over an average influenza season, 
caspofungin group were 74.9%,68.3%,70.2%, respectively; total costs were $8650.1, 
$10146.3, $9744.6, respectively. Thus, the cost-effectiveness ratio were 115.5, 148.6, 
138.8, respectively. ConClusions: Micafungin 100 mg/d group is the most cost-
effective option in the treatment of invasive Candida infection in China, followed 
by caspofungin group.
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objeCtives: Since surgical site infections (SSI) continue to impose a substantial 
burden to hospital and society, there is a need to evaluate newer SSI-prevention 
interventions such as antimicrobial (e.g., triclosan) coated sutures. Methods: We 
developed a decision analytic model using TreeAge Pro to determine the cost-effec-
tiveness of antimicrobial sutures in abdominal incisions from the hospital, third 
party payer, and societal perspectives. Sensitivity analyses systematically varied the 
risk of developing an SSI (range: 5% - 20%), cost of triclosan-coated sutures (range: $5 
- $25 per inch), and efficacy of triclosan-coated sutures to prevent infection (range: 
5% - 50%). Results: Depending on their efficacy, triclosan-coated sutures saved 
$4,109 – 13,975 (from the hospital perspective), $4,133 – 14,297 (third party payer), 
and $40,127 – 53,244 (societal) per SSI prevented, when a surgery had a 15% SSI risk. 
However, if the SSI risk after surgery was ≤ 5% and the efficacy in preventing SSIs 
was ≤ 10%, triclosan-coated sutures resulted in extra expenditure for hospitals and 
third party payers; resulting in extra costs of $1,626 and $1,071 per SSI prevented 
for hospitals and third party payers respectively, if SSI risk was 5% and efficacy was 
10%. ConClusions: Our results show that switching to triclosan-coated sutures 
from the uncoated sutures can prevent SSIs and save substantial costs to hospitals, 
third party payers, and society over a wide range of SSI prevention efficacy, cost, 
and risk values.
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objeCtives: Vaccines have been the main global means to minimize the impact of 
influenza and are recommended by WHO for individuals aged 65 years or older. The 
primary goal of influenza vaccination in the elderly is to reduce the risk of compli-
cations. Since 1998, a public-funded trivalent influenza vaccine (TIV) vaccination 
program has been implemented by the Taiwan government targeting people aged 
over 65 years. Another proposed alternative for preventing seasonal influenza is 
quadrivalent influenza vaccine (QIV) which contains two influenza A-lineages and 
two influenza B-lineages. The aim of the study is to assess, from the governmental 
perspective, the cost-effectiveness of adopting QIV versus TIV for the elderly aged 
65 years or older. Methods: A Markov model was used to estimate the cost and 
effectiveness of QIV and TIV in the elderly. Direct cost data was obtained from the 
Taiwan National Health Insurance claims data. Vaccine efficacy and coverage rate 
were based on government statistical reports. Outcomes of lifetime included cases, 
utilizations, and deaths avoided and QALYs gained. The corresponding incremental 
cost-effectiveness ratios (ICERs) were also estimated. The discount rate of cost and 
effectiveness was set at 3.5%. Results: Compared to TIV, adopting QIV would yield 
the influenza-related outcomes as follows: 26,319 influenza cases avoided, 26,021 
cases of outpatient visit avoided, 2,771 cases of influenza complication avoided, and 
330 deaths avoided. Using QIV instead of TIV would bring an additional 19,310,320 
QALYs at an extra cost of US$223.39 billion, yielding an ICER of US$35,851.3 per QALY 
gained. When herd protection of vaccination is considered, the ICER would reduce 
to US$32,660.1 per QALY gained. ConClusions: To use QIV as an alternative of 
first-line strategy to prevent seasonal influenza for the elderly in Taiwan would be 
cost-effectiveness from the governmental perspective.
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objeCtives: To assess the cost-effectiveness of the four comparators examined 
in the ACTG 5202 clinical trial, tenofovir/emtricitabine (TDF/FTC) or abacavir/
lamivudine (ABC/3TC) in combination with efavirenz (EFV) or atazanavir/ritonavir 
(ATV/r), for treatment-naïve adults with HIV-1 infection in the United Kingdom 
(UK). Methods: A Markov model with six health states based on CD4+ cell-count 
ranges was developed to estimate costs and health outcomes for individuals on first-
line therapy. Head-to-head efficacy data (lack of regimen failure and mean CD4+ cell-
count changes) up to 192 weeks for TDF/FTC+EFV, TDF/FTC+ATV/r, ABC/3TC+EFV, 
and ABC/3TC+ATV/r were obtained from the ACTG 5202 clinical trial. Antiretroviral 
drug costs were based on current list prices. Utility values, mortality, and other 
direct medical costs (2012 UK pounds) were stratified by CD4+ cell-count range 
and obtained from published sources. All outcomes were discounted at 3.5% per 
year. Sensitivity and subgroup analyses were conducted, including analysis of low 
(< 100,000 copies/mL) and high (≥ 100,000 copies/mL) baseline viral load. Results: 
Individuals using TDF/FTC-based regimens were predicted to remain on first-line 
therapy longer and accrue more QALYs than individuals using ABC/3TC-based regi-
mens (QALYs: 6.30 for TDF/FTC+EFV, 6.45 for TDF/FTC+ATV/r, 5.02 for ABC/3TC+EFV, 
and 5.26 for ABC/3TC+ATV/r). Costs were £111,882 for TDF/FTC+EFV, £124,302 for 
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plasty—compared to non-infected patients— ranged from 5.4 to 54 days. Differences 
in populations and outcome measures in studies evaluating mortality, readmissions 
and costs due to SSIs associated with hip arthroplasty precluded group analysis. 
A representative example of results from one US study reported the average total 
charges (in 2006 US$) of treating SSIs in patients who underwent primary total hip 
arthroplasty to be $73,452 compared to $38,588 to treat non-infected patients. In 
addition, a UK study showed that treating MRSA infections further exacerbated out-
comes, with excess mean LOS of 14 days and increased costs of £4,465 compared to 
non-MRSA infections in 2004. ConClusions: SSI infections after hip arthroplasty 
impose additional cost; an important portion of SSIs are associated with S. aureus. 
An unmet need for targeted preventive strategies to reduce the consequences of 
SSIs is highlighted.
INfECtIoN – Patient-reported outcomes & Patient Preference studies
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objeCtives: In a real-world setting, adherence to antiviral therapies is often sub-
par and treatment outcomes are consequently compromised. This study evaluated 
the adherence rate to HCV therapy in a Medicaid population. Methods: Patients 
eligible for this study were Texas Medicaid patients ≥ 18 years who had evidence of 
chronic HCV during the identification period (1/1/07 – 9/30/11) and were continu-
ously enrolled throughout the assessment period. Primary outcome was adher-
ence to pegylated interferon (Peg-IFN) and telaprevir (TLV) or boceprevir (BOC) as 
measured by proportion of days covered (PDC) using refill history. Univariate and 
multivariate logistic regression analysis evaluated predictors for adherence, such 
as age (< 55, ≥ 55), gender, Charlson comorbidity index (CCI), race (Whites vs. Non-
Whites), presence of medical/psychosocial comorbidities, number of prescription 
drugs and office visits (intervals of 10), and evidence of adherence to other chronic 
medications (coronary artery disease and diabetes). Results: A total of 24,032 
patients were identified as having chronic HCV; 9.4% with evidence of receiving 
HCV treatment. Of those treated, 11.2% were initiated on therapy with either TLV 
or BOC in 2011. The average HCV medication PDC was 70% with a significant dif-
ference between the first 12 weeks and the following 12 weeks of therapy (79% vs. 
60%, p< 0.001). Significant positive independent predictors of HCV medication PDC 
greater than 70% included male gender (OR: 1.42, 95% CI: 1.08-1.86), higher number 
of non-HCV prescription drugs (OR: 1.11, 95% CI: 1.02-1.21) and higher number of 
outpatient visits (OR: 1.19, 95% CI: 1.08-1.31). Age, CCI, race and adherence levels 
to other chronic medications were not significant independent predictors for HCV 
medication PDC. ConClusions: Overall adherence for HCV therapy was poor 
(70%), especially after the initial 12 weeks of therapy (60%). Closer follow-up and 
management of other comorbidities may improve readiness to HCV therapy and 
improve treatment adherence.
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objeCtives: Adults with immunocompromising conditions have higher chances 
of developing pneumococcal disease and should receive pneumococcal vaccination 
based on the recommendations by U.S. Centers for Disease Control and Prevention. 
This study examined pneumococcal vaccination in immunocompromised adults, 
including patients with chronic renal disease (CRD), cancer, HIV infection, and 
patients who underwent transplant. Methods: A large administrative claims 
database was used to assess the pneumococcal vaccination among adults aged 
19-64 years who were newly diagnosed with CRD, cancer, HIV, or patients underwent 
organ transplant procedure during 2007-2010. These patients were followed until 
2011 or the end of enrollment to identify whether they received pneumococcal vac-
cination after the diagnosis or procedure. Multivariate logistic regression was used 
to examine patients characteristics associated with pneumococcal vaccination cov-
erage. Results: We identified 22,862 patients with CRD, 216,658 with cancer, 2,576 
with HIV infection, and 41,889 patients underwent transplant procedure during the 
study period. The pneumococcal vaccination coverage were 7.3% among patients 
with newly diagnosed with CRD, 4.8% among cancer patients, 31.0% among HIV 
patients, and 5.2% among patients underwent transplant. Immunocompromised 
patients with more hospitalizations during the follow-up period had higher cover-
age, except for HIV patients. Coverage was consistently higher with more visits 
to doctor office and pharmacy across all immunocompromising conditions. The 
majority of immunocompromised patients received their vaccines at the primary 
care physician’s (PCP) office (68.4% among patients with CRD, 70.0% among can-
cer, and 75.0% among transplant) except for HIV patients (45.2% at PCP office vs. 
45.7% at specialist office). Vaccination out-of-pocket costs ranged from $3.41 (HIV) 
to $11.06(CRD) for immunocompromised patients. ConClusions: Pneumococcal 
vaccination coverage was highest in HIV patients and lowest in cancer patients 
among all immunocompromising conditions. However, even HIV population did not 
meet Healthy people 2020 target for immunocompromised patients (60%). A more 
efficient immunization strategy should be developed to improve pneumococcal 
vaccination coverage for the immunocompromised adults.
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PatIENts wIth hEPatItIs C usINg drug dual thEraPy IN both rEtaIl 
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relative to IIV3, IIV4 is expected to avert an additional 2,516 influenza cases, 1,683 
influenza-associated medical visits, 27 influenza-associated hospitalizations and 
5 influenza-associated deaths. From a societal perspective IIV4 would generate 76 
more QALYs and a net societal budget impact of $2,265,769. The incremental cost 
effectiveness ratio (ICER) for this comparison was $29,738/QALY. 74% of simulations 
in a probabilistic sensitivity analysis were below $100,000/QALY and 29% were domi-
nant. In a scenario analysis, the ICER was $94,248 per QALY from a third party payer 
perspective. ConClusions: IIV4 is expected to achieve reductions in influenza 
related morbidity and mortality compared to IIV3. Further, despite not accounting 
for herd protection IIV4 is still expected to be a cost effective alternative to IIV3. Our 
conclusions were robust in the face of sensitivity analyses.
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objeCtives: The aim of this study is to assess the economic impact of new strate-
gies involving the administration of triple therapy (PEG IFN , ribavirin and telaprevir 
or boceprevir) to naive patients with chronic hepatitis C (CHC). Methods: eco-
nomic results were evaluated along a 30 – years time horizon. Seven health states 
were considered in our model: CHC genotype 1, sustained virologic response (SVR), 
compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation and 
death. The effectiveness of telaprevir in naïve patients was inferred from ADVANCE 
trial, whilst the effectiveness of boceprevir was inferred from the SPRINT 2 trial. 
Quality of life (QoL) scores were used to adjust the years gained by patients enrolled 
in the model. Resource consumption was estimated from the Italian SSN perspec-
tive. Costs and benefits were discounted at a rate of 3.5%. To map the uncertainty of 
the model resulting from the Bayesian analysis, a probabilistic sensitivity analysis 
was carried out. Results: In both cases the ICER is likely to be under an hypotheti-
cal threshold of € 20.000 – 30.000. However, strategy which includes treatment with 
teelaprevir is proven to have a more favorable cost effectiveness ratio.(€ 12.000 vs € 
14.000). In the case of telaprevir probability of being under the threshold of € 30.000/
QALY is 100/, whist for Boceprevir probability is 70%. ConClusions: In general, the 
provision of either telaprevir and boceprevir was proved to be affordable compared 
to the standard of care.
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objeCtives: An elevated number of absence days and disability affect both employ-
ers and employees as a result of pneumococcal diseases. This study aims to estimate 
the impact of a 13-Valent Pneumococcal vaccination program from employer´s per-
spective in a medium size Mexican-Corporate setting. Methods: A decision tree 
was built in order to estimate yearly productivity losses and absence days avoided, 
as well as pneumococcal disease treatment costs. Local incidence of pneumococ-
cal diseases as well as mortality rates were extracted from published and Mexican 
Government databases. Treatment costs were retrieved from the most representa-
tive Mexican public health care provider. The cost of the vaccine was provided by the 
manufacturer. A base scenario of a 1,000 employee company with a homogeneous 
distribution of ages (18< x< 65) was assumed to show the potential benefits of the 
program in patients between 50 and 65 years old (average monthly wage: US$779). 
Productivity losses are expressed in 2013 US$ (5% discount rate/year). A bivari-
ate sensitivity analysis of both, vaccine cost (+10%) and effectiveness (-10%) was 
performed. Results: Assuming 50% employee enrollment into the program, and 
vaccination cost split 50/50 between employer and employee, a single employer 
investment of US$50 per program participant could potentially generate savings 
of US$33 for each over a ten year horizon. We estimate 395 absence days can be 
avoided, representing avoided productivity losses as high as US$8,315 across all 
participants in ten years. The program becomes cost-saving at year 7, however 
absences are avoided from the first year. The total treatment plus productivity 
losses of an invasive infection, in- and outpatient pneumonia are respectively 54, 
34 and 47 times higher than the vaccination outlay. Outcomes were robust to a 10% 
variation in both vaccination cost and effectiveness. ConClusions: A 13-Valent 
Pneumococcal vaccination program could bring potential savings for employers 
from the seventh year of implementation.
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objeCtives: SSIs are post-surgical complications that are associated with substan-
tial economic burden. Patients who undergo hip arthroplasty may develop SSIs, 
with seriously affected individuals typically requiring costly interventions including 
revision surgery or possibly removal of prostheses. The objective is to review the 
global epidemiology and burden of SSIs following hip arthroplasty, with a focus on 
Staphylococcus aureus (S. aureus). Methods: A comprehensive search was conducted 
in PubMed and relevant conference abstracts; 240 publications were reviewed to 
identify the epidemiology and burden of SSIs associated with hip arthroplasty pub-
lished between 2003 and 2013. Results: The median SSI infection rate as a percent 
of all hip arthroplasties was 1.8% (range: 0.05%-28%). Median 44% (18%-60%) of 
SSIs after hip arthroplasty were attributed to S.aureus. Methicillin-resistant S.aureus 
(MRSA) infection rates (% all S.aureus infections) from three studies were calculated 
as 16%, 31% and 56%, with variations in the range likely due to small sample size. 
Length of stay (LOS) prolongation for patients who developed SSIs after hip arthro-
